% chg: 35.4%
Swiss drug giant
Safety concerns forced the biotech company to terminate enrollment in late-stage trials of its lead drug, REG1. Regado's second experimental drug, REG2, has the same ingredients as REG1.
Most Popular Stories
- Rackspace Ends Talks About Possible Acquisition
- Mercedes Rolls Out S550 Plug-in Hybrid
- Missouri GM Plant Adding 750 jobs
- Poverty Rate Drops for First Time Since 2006
- Aaron Hernandez: I Felt Helpless to Refuse Police
- Cedeno Named USHCC Businessman of the Year
- Parameters Being Drawn for IS Action
- Anheuser-Busch, Visa Voice NFL Disapproval
- Can Kobach Keep Taylor's Name on Ballot?
- Two-thirds of Hispanics Doubt Media Accuracy